Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)

Next Previous
Trial Profile

A Phase 2 Clinical Trial to Assess the Safety and Efficacy of Complement 3 Inhibitor, AMY-101, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 (SAVE)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMY 101 (Primary)
  • Indications Adult respiratory distress syndrome; COVID-19 pneumonia
  • Focus Therapeutic Use
  • Acronyms SAVE
  • Sponsors Amyndas Pharmaceuticals

Most Recent Events

  • 19 Feb 2021 Planned End Date changed from 1 Mar 2021 to 1 Dec 2022.
  • 19 Feb 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Sep 2022.
  • 19 Feb 2021 Planned initiation date changed from 1 Jul 2020 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top